Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

56.04USD
27 Mar 2017
Change (% chg)

-- (--)
Prev Close
$56.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,975,907
52-wk High
$77.10
52-wk Low
$46.01

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb receives positive CHMP opinion recommending opdivo
Friday, 24 Mar 2017 08:31am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb receives positive chmp opinion recommending opdivo (nivolumab) for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy . Bristol-Myers Squibb Co - positive opinion based on overall survival benefit demonstrated in phase 3 checkmate -141 trial . Bristol-Myers Squibb Co- safety profile of opdivo in checkmate -141 was consistent with prior studies in other tumors .Bristol-Myers Squibb - CHMP recommendation will now be reviewed by European Commission.  Full Article

Heat Biologics reports positive results from mid-stage lung cancer trial
Tuesday, 21 Mar 2017 07:00am EDT 

Heat Biologics Inc : Heat Biologics reports positive interim phase 2 lung cancer results in patients treated with hs-110 in combination with a checkpoint inhibitor . Immune responses to hs-110 were observed in all 5 patients that exhibited tumor reductions .No tumor reductions were observed in patients that did not mount an immune response to hs-110.  Full Article

Bristol-Myers Squibb, Cytomx Therapeutics extend worldwide collaboration
Monday, 20 Mar 2017 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb and Cytomx Therapeutics extend worldwide collaboration to discover Probody Therapeutics for the treatment of cancer and other diseases . Bristol-Myers Squibb Co - Cytomx to receive $200 million upfront payment . Bristol-Myers Squibb - Cytomx will also be eligible to receive up to $448 million in future development, regulatory,sales milestone payments for each collaboration target . Bristol-Myers Squibb Co - collaboration includes up to eight additional targets in oncology and other therapeutic areas .Bristol-Myers Squibb Co - Cytomx will grant Bristol-Myers Squibb exclusive worldwide rights to develop and commercialize Probody Therapeutics.  Full Article

Transgene SA says first results from Phase 2 trial could be expected from end of 2017
Monday, 13 Mar 2017 01:00pm EDT 

Transgene SA : First patient dosed in Phase 2 trial evaluating Transgene's TG4010 in combination with Opdivo(nivolumab) for 2nd line treatment of metastatic non-small cell lung cancer (NSCLC) .First results from Phase 2 trial could be expected from end of 2017.  Full Article

Heat Biologics Meets Efficacy Endpoint in Phase 1B Lung Cancer Trial
Monday, 13 Mar 2017 07:00am EDT 

Heat Biologics Inc : Heat biologics meets efficacy endpoint in its phase 1b lung cancer trial to progress to phase 2 . Data monitoring committee (dmc) determined that phase 1b safety endpoint was met . There do not appear to be additional toxicities seen in Hs-110/Nivolumab combination compared to existing data on nivolumab alone .5 out of 15 patients treated with Hs-110/Nivolumab combination had 20% or greater tumor reduction.  Full Article

Bristol-Myers Squibb appoints Thomas Lynch as Chief Scientific Officer
Wednesday, 8 Mar 2017 12:24pm EST 

Bristol-Myers Squibb Co : Bristol-Myers Squibb appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer . Lynch succeeds Francis Cuss who will retire from company . Lynch will step down from Board of Directors of Bristol-Myers Squibb, effective March 15, 2017 .Cuss will serve as an advisor to company for next three months.  Full Article

Bristol-Myers Squibb declared a qtrly div of $0.39 per share
Thursday, 2 Mar 2017 04:34pm EST 

Bristol-Myers Squibb Co :Bristol-Myers Squibb - declared a quarterly dividend of $0.39 per share on $.10 par value common stock of corporation.  Full Article

Bristol-Myers announces equity investment in GRAIL Inc
Wednesday, 1 Mar 2017 08:10am EST 

Bristol-Myers Squibb Co : Bristol-Myers Squibb expands focus on precision medicine with investment and planned collaboration with GRAIL on blood-based cancer screening . Bristol-Myers Squibb Co - Bristol-Myers Squibb will gain early access to Grail's comprehensive clinical trial databases . Bristol-Myers Squibb Co - co, grail agreed to principal terms of a research collaboration for co to examine clinical data using GRAIL's analytic tools .Bristol-Myers Squibb Co - announced its equity investment and plans for a research collaboration with GRAIL Inc.  Full Article

Bristol-Myers Squibb prices $1.5 billion of senior notes
Wednesday, 22 Feb 2017 06:00pm EST 

Bristol-myers Squibb Co :Bristol-Myers Squibb prices $1.5 billion of senior notes.  Full Article

Bristol-Myers sees restructuring charges between $1.5-$2.0 bln through 2020
Tuesday, 21 Feb 2017 12:23pm EST 

Bristol-myers Squibb Co : Bristol-Myers Squibb says expects to incur charges through 2020, ranging between $1.5 billion to $2.0 billion in connection with restructuring announced in Oct 2016 . Bristol-Myers Squibb - Cash outlays in connection with the actions expected to be about 40% to 50% of the total charges .Bristol-Myers Squibb - Charges of about $90 million recognized during Q4, primarily from certain research and development employee workforce reductions and accelerated depreciation on expected early site exits.  Full Article

More From Around the Web

BRIEF-Bristol-Myers Squibb receives positive CHMP opinion recommending opdivo

* Bristol-Myers Squibb receives positive chmp opinion recommending opdivo (nivolumab) for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy